Midostaurin, Bortezomib and MEC in Relapsed/Refractory Acute Myeloid Leukemia

Targeting aberrant tyrosine kinase activity may impact clinical outcome in acute myeloid leukemia (AML). We conducted a phase I study of the tyrosine kinase inhibitor midostaurin with bortezomib alone and in combination with chemotherapy in patients with AML. Patients on dose levels 1 and 2 (DL1 &am...

Descripción completa

Guardado en:
Detalles Bibliográficos
Publicado en:Leuk Lymphoma
Autores principales: Walker, Alison R., Wang, Hongyan, Walsh, Katherine, Bhatnagar, Bhavana, Vasu, Sumithira, Garzon, Ramiro, Canning, Renee, Geyer, Susan, Wu, Yue-Zhong, Devine, Steven M., Klisovic, Rebecca, Blum, William, Marcucci, Guido
Formato: Artigo
Lenguaje:Inglês
Publicado: 2016
Materias:
Article
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC5360182/
https://ncbi.nlm.nih.gov/pubmed/26784138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3109/10428194.2015.1135435
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares